Halcion Related Published Studies
Well-designed clinical trials related to Halcion (Triazolam)
Modulation of the discriminative stimulus effects of triazolam across the menstrual cycle phase in healthy pre-menopausal women. [2008.04.01]
Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. [2006.11]
Dose effects of triazolam on brain activity during episodic memory encoding: a PET study. [2006.11]
Decreasing pain and anxiety associated with patient-activated atrial shock: a placebo-controlled study of adjunctive sedation with oral triazolam. [2006.04]
Effect of benzodiazepine hypnotic triazolam on relationship of blood pressure and Paco2 to cerebral blood flow during human non-rapid eye movement sleep. [2006.04]
Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. [2006.03]
An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers. [2005.11]
Pharmocokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test. [2005.09]
Zolpidem and triazolam do not affect the nocturnal sleep-induced memory improvement. [2005.08]
Temporal changes in postural sway caused by ultrashort-acting hypnotics: triazolam and zolpidem. [2005]
Well-designed clinical trials possibly related to Halcion (Triazolam)
Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. [2007.03]
Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. [2006.03]
Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies. [2006.01]
Zaleplon (Sonata) oral sedation for outpatient third molar extraction surgery. [2005.01]
Other research related to Halcion (Triazolam)
Effect of sublingual triazolam on the success of inferior alveolar nerve block in patients with irreversible pulpitis. [2008.10]
Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effects. [2007.08]
A triazolam/amphetamine dose-effect interaction study: dissociation of effects on memory versus arousal. [2007.06]
Pharmacokinetics and clinical effects of multidose sublingual triazolam in healthy volunteers. [2006.02]
Discriminative-stimulus effects of triazolam in women and men. [2006]
Comparison of the behavioral effects of bretazenil and flumazenil in triazolam-dependent and non-dependent baboons. [2005.09.05]
Criminal injury case using vegetable juice intermixed with triazolam. [2005.08]
Urinary excretion profiles of two major triazolam metabolites, alpha-hydroxytriazolam and 4-hydroxytriazolam. [2005.05]
Hallucinations and delirium in the dental office following triazolam administration. [2005.03]
Discriminative stimulus and self-reported effects of methylphenidate, d-amphetamine, and triazolam in methylphenidate-trained humans. [2005.02]
Other possibly related research studies
Practical oral sedation in dentistry. Part II--Clinical application of various oral sedatives and discussion. [2006.09]
Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. [2006.10]
Potentiation of ethanol in spatial memory deficits induced by some benzodiazepines. [2006.08]
Balancing efficacy and safety in the use of oral sedation in dental outpatients. [2006.04]
Calculating and justifying total anxiolytic doses of medications for in-office use. [2006.01]
The use of anxiolytic medications to supplement local anesthesia in the anxious patient. [2005.03]
Combined discriminative stimulus effects of midazolam with other positive GABAA modulators and GABAA receptor agonists in rhesus monkeys. [2005.04]
A fatal poisoning caused by methomyl and nicotine. [2005.05.10]
Drug use and HIV/AIDS in China. [2006.03]
Quetiapine for insomnia associated with refractory depression exacerbated by phenelzine. [2006.03]
Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. [2005]
Benefit-risk assessment of zaleplon in the treatment of insomnia. [2005]
Maximum cumulative doses of sedation medications for in-office use. [2007.03]
Adult oral sedation in California: what can a dentist do without a special permit or certificate from the Dental Board of California? [2006.12]
Effectiveness and safety of hypnotic drugs in the treatment of insomnia in over 70-year old people. [2007]
Enteral sedation: safety, efficacy, and controversy. [2007.05]
Pharmacological manipulations of arousal and memory for emotional material: effects of a single dose of methylphenidate or lorazepam. [2007.07.02]
Beating jet lag. [2007.06]
Pharmacological manipulations of arousal and memory for emotional material: effects of a single dose of methylphenidate or lorazepam. [2007.09]
Chronic ethanol intake modulates photic and non-photic circadian phase responses in the Syrian hamster. [2007.08]
Sustained inhibition of brotizolam induced anterograde amnesia by norharmane and retrograde amnesia by L-glutamic acid in mice. [2007.08.22]
Evidence of safety for individualized dosing of enteral sedation. [2007.09]
What every dentist should know about the "z-sedatives". [2007.09]
Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. [2008]
Venlafaxine-propafenone interaction resulting in hallucinations and psychomotor agitation. [2008.03]
High prevalence of HCV in a cohort of injectors on methadone substitution treatment. [2008.04]
Evaluation of anxiolytic-like effects of some short-acting benzodiazepine hypnotics in mice. [2008.07]
Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. [2008.07]
|
